Paper Details

  1. Home
  2. Paper Details

Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial.

Author: BaikC S, BoralA L, BowlesD W, CuriglianoG, GainorJ F, GarraldaE, GriesingerF, HouvrasY, KalemkerianG P, KimD-W, KongS, LeeD H, LinJ J, LiuS V, Louie-GaoM, MansfieldA S, MazièresJ, MischD, Paz-AresL, RahmanA, SmoljanovicV, SubbiahV, TanD S W, ThomasM, ZalutskayaA, van der WekkenA J

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Pralsetinib, a selective RET inhibitor, showed clinical activity in patients with RET fusion-positive non-small-cell lung cancer (NSCLC), including treatment-naive patients, as demonstrated in the ARROW study. This updated analysis provides further insights into the effectiveness of pralsetinib.
Paper Details　
Original Abstract of the Article :
RET fusions are present in 1%-2% of non-small-cell lung cancer (NSCLC). Pralsetinib, a highly potent, oral, central nervous system-penetrant, selective RET inhibitor, previously demonstrated clinical activity in patients with RET fusion-positive NSCLC in the phase I/II ARROW study, including among t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.annonc.2022.08.002

データ提供：米国国立医学図書館（NLM）

Pralsetinib: A New Oasis in the Desert of RET Fusion-Positive Lung Cancer

Lung cancer, a formidable foe, often leaves patients facing a desolate desert of treatment options. This study explores the potential of pralsetinib, a selective RET inhibitor, for treating patients with RET fusion-positive non-small-cell lung cancer (NSCLC). Researchers [研究手法] to assess the safety and efficacy of pralsetinib in various settings, including as first-line therapy. The results demonstrate the promise of pralsetinib as a targeted therapy for this specific type of lung cancer.

A New Weapon in the Arsenal Against Lung Cancer

The study found that pralsetinib [研究結果] These findings highlight the potential of pralsetinib to significantly improve outcomes for patients with RET fusion-positive NSCLC, providing a much-needed oasis in the desert of treatment options. Further research is needed to optimize pralsetinib therapy and explore its potential in combination with other treatments.

Finding Hope in the Desert of Lung Cancer

This study offers a ray of hope for patients with RET fusion-positive NSCLC. Pralsetinib provides a targeted approach to treatment, offering the potential for significant benefits and improved outcomes. This research serves as a reminder of the importance of ongoing innovation in cancer therapy.

Dr. Camel's Conclusion

Like a camel finding a hidden spring in the desert, pralsetinib offers a new source of hope for patients with RET fusion-positive lung cancer. This study highlights the importance of personalized medicine and the ongoing search for targeted therapies to combat this challenging disease.

Date :
  1. Date Completed 2022-11-03
  2. Date Revised 2022-12-11
Further Info :

Pubmed ID

35973665

DOI: Digital Object Identifier

10.1016/j.annonc.2022.08.002

Related Literature

Article Analysis
・Effects of pralsetinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.